Quantum BioPharma Ltd. (QNTM)
Market Cap | 17.63M |
Revenue (ttm) | n/a |
Net Income (ttm) | -14.20M |
Shares Out | 2.71M |
EPS (ttm) | -12.49 |
PE Ratio | n/a |
Forward PE | n/a |
Dividend | n/a |
Ex-Dividend Date | n/a |
Volume | 92,466 |
Open | 6.71 |
Previous Close | 6.85 |
Day's Range | 6.45 - 6.89 |
52-Week Range | 2.70 - 31.20 |
Beta | 0.85 |
Analysts | n/a |
Price Target | n/a |
Earnings Date | May 6, 2025 |
About QNTM
Quantum BioPharma Ltd., together with its subsidiaries, operates as a biopharmaceutical company in the United States. It operates through two segments, Biopharmaceutical Innovation and Strategic Investments. The company researches and develops a portfolio of assets and biotech solutions for the treatment of neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to... [Read more]
News

Quantum BioPharma to Host Business Update Conference Call on Tuesday, May 6, 2025 at 4:30 p.m. Eastern Time
TORONTO, April 24, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) “Quantum BioPharma” or the “Company”), today announced it will host a Business Update Conferen...

Quantum Biopharma Announces Advocate Against Naked Short Selling and Stock Manipulation, Kevin Malone Appointed as Board Advisor
TORONTO, April 22, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce the appointment of Kevin Malone...

Quantum BioPharma Corporate Update
Toronto, Ontario--(Newsfile Corp. - April 18, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (Upstream: QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company...

Quantum Biopharma Wins Reconsideration Motion by Dr. Raza Bokhari at the Court of Appeal for Ontario
Awards in favour of Quantum BioPharma Totalling $180,000 upheld and is now due Awards in favour of Quantum BioPharma Totalling $180,000 upheld and is now due

Quantum BioPharma Licensee Celly Nutrition Launches unbuzzd in Puerto Rico
Alcohol Detoxification and Anti-Hangover Beverage (Available on amazon.com and unbuzzd.com) to be Distributed by FUSION in Puerto Rico and Caribbean Region TORONTO, April 03, 2025 (GLOBE NEWSWIRE) --...

Quantum BioPharma Announces Joint Clinical Study With Massachusetts General Hospital Scientists to Validate a Novel Positron Emission Tomography (PET) Imaging Technique to Monitor Demyelination In Multiple Sclerosis
TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) “Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated to building a por...

Quantum Biopharma Announces Closing of Final $2.42 Million Tranche of $5 Million Total Financing on Improved Terms
TORONTO, March 31, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”) is pleased to announce that it has closed the final tra...

Quantum BioPharma Provides Corporate Update
Toronto, Ontario--(Newsfile Corp. - March 30, 2025) - Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to bui...
Overlooked Stock: QNTM
Quantum's in the name but has no part of the business. Quantum BioPharma (QNTM) is up over 130% year to date but has fallen more than 50% off its all-time high.

Quantum Biopharma's 2024 Financial Statements Show Strong Improvements in Cash, Working Capital, Operating Efficiency and the Removal of Material Uncertainty Related to Going Concern
Completion of unbuzzdTM Clinical Trial and Multiple Sclerosis Drug Lucid-21-302 Phase 1 Trial Advance Company's Pipeline of Products and Assets TORONTO, ONTARIO / ACCESS Newswire / March 28, 2025 / Qu...

Quantum BioPharma Continues to Grow Its Crypto Assets and Diversify Its Treasury With the Purchase of Another USD $1,500,000 Worth of Bitcoin (BTC) and Other Cryptocurrencies
TORONTO, March 20, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that after receiving approval f...

Quantum BioPharma Unaware of Any Material Change
Toronto, Ontario--(Newsfile Corp. - March 17, 2025) - At the request of the Canadian Investment Regulatory Organization, Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FSE: 0K91) (the "Company") w...

Quantum Biopharma Engages MZ Group to Lead Strategic Investor Relations and Shareholder Communications Program
TORONTO, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated ...

Quantum Biopharma Engages Enterprise Canada and Empire Market Ventures to Lead Public Communications and Investor Awareness Programs
TORONTO, Feb. 10, 2025 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (Upstream: QNTM) (“Quantum BioPharma” or the “Company”), a biopharmaceutical company dedicated ...

Quantum Biopharma Licensee Celly Nutrition Retains Leading New York Investment Bank to Advise on Capital Raise and Possible Initial Public Offering Following Highly Positive Results from unbuzzd™ Clinical Study
QUANTUM BIOPHARMA PARTNER CELLY NUTRITION RETAINS LEADING NEW YORK INVESTMENT BANK TO ADVISE ON CAPITAL RAISE AND POSSIBLE INITIAL PUBLIC OFFERING FOLLOWIN

Quantum Biopharma Announces the Success of unbuzzd™ Clinical Trial
Trial Confirms unbuzzd™ Dramatically Accelerates Alcohol Metabolism, Speeds the Reduction of Blood Alcohol Concentration, and Reduces Symptoms of Intoxication, Impairment and Hangover Trial Confirms u...

Quantum Biopharma in Court With Dr. Raza Bokhari on January 24, 2025 Seeking a Court Order to Declare Him to Be a Vexatious Litigant and Other Litigation Updates
Awards in favour of Quantum BioPharma Total Approximately $3 Million TORONTO, ON / ACCESS Newswire / January 17, 2025 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) (Upstream: QNTM) ("Quan...

Quantum Biopharma Ltd. Now Trading on Upstream Under QNTM
TORONTO, ON / ACCESSWIRE / January 14, 2025 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91)(Upstream:QNTM) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to b...

Quantum Biopharma Ltd. Approved to Dual List on Upstream
Trading to become available January 14th under 'QNTM' TORONTO, ONTARIO / ACCESSWIRE / January 7, 2025 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"),...

Quantum Biopharma Announces Closing of Second Tranche
TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce that it has closed a second tranc...

Quantum Biopharma Diversifies Treasury With the Purchase of USD $1,000,000 of Bitcoin (BTC) and Other Cryptocurrencies and to Allow for Future Financings and Other Transactions in Cryptocurrency
TORONTO, ON / ACCESSWIRE / December 20, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce that after receiving approval fro...

Quantum BioPharma Diversifies Treasury with the Purchase of USD $1,000,000 of Bitcoin (BTC) and Other Cryptocurrencies and to Allow for Future Financings and Other Transactions in Cryptocurrency
TORONTO, Dec. 20, 2024 (GLOBE NEWSWIRE) -- Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) (FRA: 0K91) (“Quantum BioPharma” or the “Company”), is pleased to announce that after receiving approval fr...

Quantum Biopharma Announces Closing of First Tranche
TORONTO, ONTARIO / ACCESSWIRE / December 13, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), is pleased to announce that it has closed an initia...

Quantum Biopharma Announces That the Safety Review Committee Recommends Commencing Dosing of Second Cohort in the Phase 1 Multiple Ascending Dose Clinical Trial for Lucid-21-302 (Lucid-MS)
TORONTO, ON / ACCESSWIRE / December 10, 2024 / Quantum BioPharma Ltd. (NASDAQ:QNTM)(CSE:QNTM)(FRA:0K91) ("Quantum BioPharma" or the "Company"), a biopharmaceutical company dedicated to building a port...

Quantum Biopharma Announces Non-Brokered Private Placement of Convertible Debenture Units for Gross Proceeds of Up to $5 Million
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT INTENDED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES. TORONTO, ON / ACCESSWIRE / ...